MORGANTOWN, W. Va., Jan. 9, 2013 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea"), a leading bioanalytics technology company, announced today that Stephen Turner, the company's CEO, will present at the 15th Annual Needham & Co. Growth Conference on Tuesday January 15th, at 2:10 PM ET at the Palace Hotel in New York City. Mr. Turner will be discussing the Company's groundbreaking LAESI technology platform and how the company is building a new life science franchise by offering technologies that allow biologists to obtain full mass spectrometry imaging datasets on their tissue, cell or biofluid samples without sample preparation, as well as to study biodynamics in living colonies.
"We are honored to be presenting at the Needham Growth Conference, which features emerging growth companies such as Protea," stated Stephen Turner, CEO. "We look forward to highlighting our commercial progress, and the large market opportunity for our company's products and services."
In addition to providing LAESI DP-1000 instruments to bioanalytical laboratories worldwide, the company recently announced the opening of its Mass Spectrometry Imaging Center (MSIC) in Morgantown, WV, where biologists can directly access LAESI's powerful bioanalytical capabilities and Protea's scientific team for their research projects.
Protea's LAESI (Laser Ablation Electrospray) technology allows two and three dimensional distribution profiles of biomolecules in biological samples for unambiguous drug / target interaction studies, as well as the study of biodynamics directly from living cells. Using LAESI mass spectrometry, large numbers of biomolecules can be rapidly identified and spatially mapped to cell structures, tissues, and fluids.
A webinar replay of the presentation will be available at: www.proteabio.com
More information about the upcoming Needham conference can be found at: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx
About Protea Biosciences Group, Inc.
Protea is a leader in the field of bioanalytics – the identification and characterization of proteins, metabolites, lipids, and other biomolecules, which are the products of all living cells and life forms – technology that is foundational for all pharmaceutical and life science research.
The Protea Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10808
About Needham & Co.
Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. http://www.needhamco.com/Home_new.aspx
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.